An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.04.28.441832: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Samples were collected under consent at donation centers in Heildelberg or Munich, from 30 individual who recovered from moderate SARS-CoV-2 infection with no need for hospitalization or heavy treatment.
Field Sample Permit: The animal studies were conducted under ethics protocols approved by the National Research Council of Canada Animal Care Committee.
IACUC: The animal studies were conducted under ethics protocols approved by the National Research Council of Canada Animal Care Committee.
IRB: The study was conducted under approval of the CCAC committee at the Vaccine and Infectious Disease Organization (VIDO) International Vaccine Centre (Saskatchewan,Canada).Sex as a biological … SciScore for 10.1101/2021.04.28.441832: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Samples were collected under consent at donation centers in Heildelberg or Munich, from 30 individual who recovered from moderate SARS-CoV-2 infection with no need for hospitalization or heavy treatment.
Field Sample Permit: The animal studies were conducted under ethics protocols approved by the National Research Council of Canada Animal Care Committee.
IACUC: The animal studies were conducted under ethics protocols approved by the National Research Council of Canada Animal Care Committee.
IRB: The study was conducted under approval of the CCAC committee at the Vaccine and Infectious Disease Organization (VIDO) International Vaccine Centre (Saskatchewan,Canada).Sex as a biological variable Mouse immunization study: Six- to 8-week-old female C57BL/6 mice were purchased from Jackson Laboratory (ME, USA). Randomization Mice were randomly assigned to experimental groups and received intraperitoneal (IP) injections with 0.5 mL of different adjuvanted SARS-CoV-2 immunogens. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Alternatively, human sera from COVID-19 convalescent subjects was used as primary antibody followed by detection with goat anti-human IgG heavy and light chain HRP-conjugated (Bethyl). anti-human IgGsuggested: NoneAntibody binding titers: Anti-SARS-CoV-2 specific IgG binding titers in mouse sera were measured by standard ELISA procedure described elsewhere [18], using recombinant SARS-CoV-2 S (S1+S2) protein (Sinobiological). Anti-SARS-CoV-2suggested: NoneGoat anti-Hamster IgG HRP from ThermoFisher (PA1-29626) was used as the secondary antibody at 1:7000. Goat anti-Hamster IgG HRPsuggested: (Thermo Fisher Scientific Cat# PA1-29626, RRID:AB_10985385)anti-Hamster IgGsuggested: (Thermo Fisher Scientific Cat# PA1-29626, RRID:AB_10985385)After incubation, the plates were washed and IFN-γ capture antibody was added, followed by streptomycin horseradish peroxidase (strep-HRP). IFN-γsuggested: NoneExperimental Models: Cell Lines Sentences Resources COVID-19 human sera: Plasma samples were purchased from Biomex GmbH (Heidelberg, Germany). COVID-19suggested: NoneResults were represented as PRNT90, PRNT80, or PRNT50 end point titer, corresponding to the lowest dilution inhibiting respectively 90% or 80% or 50% of plaque formation in Vero cell culture. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)The study was conducted using the cell line Vero E6. Vero E6suggested: RRID:CVCL_XD71)Experimental Models: Organisms/Strains Sentences Resources Mouse immunization study: Six- to 8-week-old female C57BL/6 mice were purchased from Jackson Laboratory (ME, USA). C57BL/6suggested: NoneRecombinant DNA Sentences Resources Plasmids, eVLPs production and adjuvant formulation: All sequences coding for the full length and modified S proteins from SARS-CoV-2 were codon optimized prior to synthesis and subcloned into a proprietary modified phCMV plasmid at Genscript (Piscataway, NJ). phCMVsuggested: RRID:Addgene_15802)Software and Algorithms Sentences Resources Slides were examined by a board-certified pathologist. 2.12. Statistics: All statistical analyses were performed using GraphPad Prism 9 software (La Jolla, CA). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04773665 Active, not recruiting Safety, Tolerability, and Immunogenicity of the COVID-19 Vac… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
